SIX1 and breast cancer: In addition, Farabaugh et al. showed that in BC, SIX1 cooperated with its co-activator EYA2 to induce the activation of the TGF-β signaling pathway, thereby promoting the malignant biological behavior of cancer cells, such as EMT, and the proliferation of cancer stem cells [63].